Covid-19: Americans who are over 50 or immunocompromised are advised to have second booster

Tanne, Janice Hopkins

doi:10.1136/bmj.o842

Cited by 4 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these patients, an alternative protection method might be necessary. A study group reported that heterologous boosters increased immune response [10], and another group speculated that a second booster (fourth dose) gives immunocompromised patients extra protection from COVID-19 [11]. However, sufficient data are not yet available.…”

Section: Discussionmentioning

confidence: 99%

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

et al. 2022

View full text Add to dashboard Cite

Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that a second booster vaccine might indeed be useful for elderly and immunocompromised patients (Arbel et al. 2022 , Tanne 2022 ). Lastly, to illustrate the possibility of using our simulation tool to combine different interventions, the effect of elderly-only vaccination was observed in different landscapes involving transmission-limiting interventions (such as lockdown) in the elderly population only or in a generalized intervention (Fig.…”

Section: Discussionmentioning

confidence: 99%

Simulating the efficacy of vaccines on the epidemiological dynamics of SARS-CoV-2 in a membrane computing model

et al. 2022

View full text Add to dashboard Cite

Membrane computing is a natural computing procedure inspired in the compartmental structure of living cells. This approach allows mimicking the complex structure of biological processes, and, when applied to transmissible diseases, can simulate a virtual ‘epidemic’ based on interactions between elements within the computational model according to established conditions. General and focused vaccination strategies for controlling SARS-Cov-2 epidemics have been simulated for 2.3 years from the emergence of the epidemic in a hypothetical town of 10320 inhabitants in a country with mean European demographics where COVID-19 is imported. The age and immunological-response groups of the hosts and their lifestyles were minutely examined. The duration of natural, acquired immunity influenced the results; the shorter the duration, the more endemic the process, resulting in higher mortality, particularly among elderly individuals. During epidemic valleys between waves, the proportion of infected patients belonging to symptomatic groups (mostly elderly) increased in the total population, a population that largely benefits from standard double vaccination, particularly with boosters. There was no clear difference when comparing booster shots provided at 4 or 6 months after standard double-dose vaccination. Vaccines even of moderate efficacy (short-term protection) were effective in decreasing the number of symptomatic cases. Generalized vaccination of the entire population (all ages) added little benefit to overall mortality rates, and this situation also applied for generalized lockdowns. Elderly-only vaccination and lockdowns, even without general interventions directed to reduce population transmission, is sufficient for dramatically reducing mortality.

show abstract

“…Contemporary evidence indicates that a second booster dose can enhance the immunogenicity of COVID-19 vaccines in these crucial groups, thereby augmenting vaccine effectiveness and reducing risks of infection, severe illness, hospitalization, and death ( 15 , 16 ). To further substantiate this, the United States Food and Drug Administration (FDA) and China’s Bureau of Disease Control and Prevention endorse an additional booster dose for immunocompromised individuals, including the older adults and adults suffering from severe underlying conditions such as cancer, after completing the primary three-dose COVID-19 vaccination regimen ( 12 , 17 ).…”

Section: Introductionmentioning

confidence: 99%

“…Nonetheless, evidence points toward a gradual decrease in vaccine effectiveness against SARS-CoV-2 following the primary immunization schedule (9)(10)(11). Notably, this decline is more conspicuous among cancer patients and the older adults relative to their healthier counterparts (12)(13)(14). Contemporary evidence indicates that a second booster dose can enhance the immunogenicity of COVID-19 vaccines in these crucial groups, thereby augmenting vaccine effectiveness and reducing risks of infection, severe illness, hospitalization, and death (15,16).…”

Section: Introductionmentioning

confidence: 99%

Willingness to receive the second booster of COVID-19 vaccine among older adults with cancer: a stratified analysis in four provinces of China

Zhang,

Yang,

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundDespite the elevated COVID-19 risk for older adults with cancer, vaccine hesitancy poses a significant barrier to their immunization. Intriguingly, there is limited research on the prevalence of willingness to receive the second booster dose and associated determinants in older adults with cancer.ObjectiveOur objective was to ascertain the level of awareness about COVID-19 vaccines and to uncover the factors influencing the willingness to receive the second booster among Chinese cancer patients aged 65 years and over.MethodsTo achieve our objective, we conducted a multicenter cross-sectional study in four tertiary hospitals from four provinces of China. This involved using a Health Belief Model (HBM) based self-administered questionnaire and medical records. Subsequently, we employed multivariable logistic regression to identify factors influencing the second COVID-19 booster vaccine willingness.ResultsOur results showed that among 893 eligible participants, 279 (31.24%) were aged 65 years and over, and 614 (68.76%) were younger. Interestingly, the willingness to receive the second COVID-19 booster vaccine was 34.1% (95/279) (OR: 1.043, 95% CI: 0.858, 1.267) in participants aged 65 years and over, which was similar to participants aged under 65 years (34.1% vs. 35.5%, p = 0.673). Furthermore, our findings revealed that a positive attitude toward the booster and recommendations from healthcare providers and family members were positively associated with vaccine willingness. Conversely, perceptions of negative impacts on cancer control and vaccine accessibility regarding the second COVID-19 booster were inversely related to the outcome event (all p < 0.05).ConclusionOur study concludes with the finding of a low willingness toward the second COVID-19 booster in Chinese cancer patients, particularly in the older adults, a fact which warrants attention. This reluctance raises their risk of infection and potential for severe outcomes. Consequently, we recommend using media and community outreach to dispel misconceptions, promote the booster’s benefits, and encourage vaccine discussions with healthcare providers and family members.

show abstract

Covid-19: Americans who are over 50 or immunocompromised are advised to have second booster

Cited by 4 publications

References 2 publications

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

Simulating the efficacy of vaccines on the epidemiological dynamics of SARS-CoV-2 in a membrane computing model

Willingness to receive the second booster of COVID-19 vaccine among older adults with cancer: a stratified analysis in four provinces of China

Contact Info

Product

Resources

About